Medicare Covers GLP-1 Weight-Loss Drugs Starting July 1
For the first time, qualifying Medicare enrollees can access GLP-1 weight-loss medications for just $50 a month beginning July 1.
Big news if you're on Medicare and have been eyeing those weight-loss drugs everyone keeps talking about: starting July 1, qualifying beneficiaries will finally have access to GLP-1 medications for weight loss — and the cost is capped at $50 a month. That's a pretty significant shift, since Medicare hasn't historically covered these drugs when prescribed specifically for obesity or weight management.
GLP-1s — shorthand for glucagon-like peptide-1 receptor agonists — are the class of drugs that includes household names like Ozempic and Wegovy. They work by mimicking a hormone that regulates appetite, helping people feel fuller faster and eat less overall. They've taken the health world by storm, but their sticker price without insurance can run into hundreds or even thousands of dollars per month, putting them out of reach for many retirees on fixed incomes.
Read more Working in Retirement? Here's How Social Security Cuts Work →
Before you call your doctor, there are a few things worth knowing. Not every Medicare enrollee will automatically qualify — you'll need to meet certain eligibility criteria, so it's worth checking with your plan or healthcare provider before assuming you're covered. And like any medication, GLP-1s come with trade-offs you should discuss openly with your doctor.
The side effects are real and worth taking seriously. Beyond the commonly reported nausea and digestive issues, one concern that doesn't get enough attention is muscle loss. Rapid weight reduction — especially in older adults — can mean losing lean muscle mass alongside fat, which can affect mobility, strength, and overall health. Pairing these medications with resistance exercise and adequate protein intake is something many doctors now recommend to help offset that risk.
Bottom line: this is a meaningful expansion of Medicare coverage that could improve health outcomes for millions of older Americans, but it pays to go in informed. Continue reading at MarketWatch.com
